SynAct Pharma Aps: Clinical Trials

3 completed, 3 recruiting. 6 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 3, Recruiting 3

Follow SynAct Pharma Aps: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses AP1189, 100 mg, Placebo - Respiratory Viral Infection	Phase 2	Recruiting	SynAct Pharma Aps	96	2026-05-01	2026-07-28
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg - Rheumatoid Arthritis (RA)	Phase 2	Recruiting	SynAct Pharma Aps	240	2024-10-01	2025-10-06
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate AP1189, 60 mg, AP1189, 80 mg, AP1189, 100 mg - Rheumatoid Arthritis	Phase 2	Completed	SynAct Pharma Aps	125	2022-11-30	2024-11-06
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment 100 mg AP1189, Placebo - Rheumatoid Arthritis	Phase 2	Completed	SynAct Pharma Aps	127	2022-09-26	2023-11-07
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria 100 mg AP1189, Placebo - Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy	Phase 2	Recruiting	SynAct Pharma Aps	23	2020-08-31	2026-03-06
A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease 50 mg AP1189, AP1189, Placebo - Rheumatoid Arthritis	Phase 2	Completed	SynAct Pharma Aps	105	2019-08-26	2024-07-10

Conditions studied

Arthritis, Rheumatoid (4)  ·  Influenza, Human (1)

Interventions

N-(3-(1-(2-nitrophenyl)-1H-pyrrol-2-yl)allylidenamino)guanidine (6)

Countries

Denmark (3)  ·  Moldova (3)  ·  Bosnia and Herzegovina (1)  ·  Bulgaria (1)  ·  Montenegro (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Poland (1)  ·  Serbia (1)  ·  United States (1)

Top investigators

Ellen-Margrethe Hauge, Professor (1)  ·  Espen A Haavardsholm, Concultant, PhD (1)  ·  Henrik Birn, Professor (1)